ProCE Banner Activity

UNITY-NHL: Umbralisib Monotherapy in Patients With R/R Indolent NHL

Slideset Download
Conference Coverage
Umbralisib monotherapy associated with a 47% response rate in heavily pretreated patients with relapsed/refractory marginal zone lymphoma, follicular lymphoma, or small lymphocytic lymphoma.

Released: December 18, 2020

Expiration: December 17, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology